Abstract
Therapeutic drug monitoring (TDM) represents an early approach to personalised medicine. It helps the clinician to individualise drug treatment and guide dosage to reach systemic drug concentrations associated with therapeutic efficacy and/or to reduce the risk of concentration-dependent adverse effects. Well into the fifth decade of TDM as a service to healthcare, this concept is still expanding, and new areas for clinical implementation continue to emerge. The aim of this overview is to discuss promising new therapeutic areas in future TDM services, how to improve the clinical interpretation of single drug measurements and how recent technology development opens the doors to research and new applications.
Similar content being viewed by others
References
Birkett D, Brøsen K, Cascorbi I, Gustafsson LL, Maxwell S, Rago L, Rawlins M, Reidenberg M, Sjöqvist F, Smith T, Thuerman P, Walubo A, Orme M, Sjöqvist F (2010) Clinical pharmacology in research, teaching and health care: considerations by IUPHAR, the International Union of Basic and Clinical Pharmacology. Basic Clin Pharmacol Toxicol 107:531–559
Asberg M, Cronholm B, Sjöqvist F, Tuck D (1971) Relationship between plasma level and therapeutic effect of nortriptyline. Br Med J 3:331–334
Noone P, Parsons TM, Pattison JR, Slack RC, Garfield-Davies D, Hughes K (1974) Experience in monitoring gentamicin therapy during treatment of serious Gram-negative sepsis. Br Med J 1:477–481
Duhme DW, Greenblatt DJ, Koch-Weser J (1974) Reduction of digoxin toxicity associated with measurement of serum levels. A report from the Boston Collaborative Drug Surveillance Program. Ann Intern Med 80:516–519
Levy G, Ellis EF, Koysooko R (1974) Indirect plasma-theophylline monitoring in asthmatic children by determination of theophylline concentration in saliva. Pediatrics 53:873–876
Eichelbaum M, Bertilsson L, Lund L, Palmér L, Sjöqvist F (1976) Plasma levels of carbamazepine and carbamazepine-10,11-epoxide during treatment of epilepsy. Eur J Clin Pharmacol 9:417–421
Sjöqvist F, Eliasson E (2007) The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine: focus on antidepressants. Clin Pharmacol Ther 81:899–902
Dahl M-L, Sjöqvist F (2000) Pharmacogenetic methods as a comment to therapeutic monitoring of antidepressants and neuroleptics. Ther Drug Monit 22:114–116
Saint-Marcoux F, Sauvage FL, Marquet P (2007) Current role of LC-MS in therapeutic drug monitoring. Anal Bioanal Chem 388:1327–1340
Sallustio BC (2010) LC-MS/MS for immunosuppressant therapeutic drug monitoring. Bioanalysis 2:1141–1153
Meyer MR, Maurer HH (2012) Current applications of high-resolution mass spectrometry in drug metabolism studies. Anal Bioanal Chem 403:1221–1231
Mittelstrass K, Ried JS, Yu Z, Krumsiek J, Gieger C, Prehn C, Roemisch-Margl W, Polonikov A, Peters A, Theis FJ, Meitinger F, Krononberg F, Weidinger S, Wichmann HE, Suhre K, Wang-Sattler R, Adamski J, Illig T (2011) Discovery of sexual dimorphism in metabolic and genetic biomarkers. PLoS Genet 7:1–11
Broecker S, Herre S, Wüst B, Zweigenbaum J, Pragst F (2011) Development and practical application of a library of CID accurate mass spectra of more than 2,500 toxic compounds for systematic toxicological analysis by LC-QTOF-MS with data-dependent acquisition. Anal Bioanal Chem 400:101–117
Heine R, Beijnen JH, Huitema AD (2009) Bioanalytical issues in patient friendly sampling methods for therapeutic drug monitoring: focus on antiretroviral drugs. Bioanalysis 1:1329–1338
Gallardo E, Barroso M, Queiroz JA (2009) Current technologies and considerations for drug bioanalysis in oral fluid. Bioanalysis 1:637–667
Sime FB, Roberts MS, Peake SL, Lipman J, Roberts JA (2012) Does beta-lactam pharmacokinetic variability in critically ill patients justify therapeutic drug monitoring? A systematic review. Ann Intensive Care 2:35
Roberts DM, Roberts JA, Roberts MS, Liu X, Nair P, Cole L, Lipman J, Bellomo R, RENAL Replacement Therapy Study Investigators (2012) Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study. Crit Care Med 40:1523–1528
Udy AA, Roberts JA, De Waele JJ, Paterson DL, Lipman J (2012) What’s behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance. Int J Antimicrob Agents 39:455–457
González de Molina FJ, Ferrer R (2011) Appropriate antibiotic dosing in severe sepsis and acute renal failure: factors to consider. Crit Care 15:175
Taccone FS, Laterre PF, Dugernier T, Spapen H, Delattre I, Wittebole X, De Backer D, Layeux B, Wallemacq P, Vincent JL, Jacobs F (2010) Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care 14:R126
Hanberger H, Edlund C, Furebring M, G Giske C, Melhus A, Nilsson LE, Petersson J, Sjölin J, Ternhag A, Werner M, Eliasson E; Swedish Reference Group for Antibiotics (SRGA) (2012) Rational use of aminoglycosides—Review and recommendations by the Swedish Reference Group for Antibiotics (SRGA). Scand J Infect Dis 45(3):161–75
Pasqualotto AC, Howard SJ, Moore CB, Denning DW (2007) Flucytosine therapeutic monitoring: 15 years’ experience from the UK. J Antimicrob Chemother 59:791–793
Rybak M, Lomaestro B, Rotschafer JC et al (2009) Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 66:82–98
Hazlewood KA, Brouse SD, Pitcher WD, Hall RG (2010) Vancomycin-associated nephrotoxicity: grave concern or death by character assassination? Am J Med 123:182.e1–182.e7
Lodise TP, Lomaestro B, Graves J, Drusano GL (2008) Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 52:1330–1336
Van Herendael B, Jeurissen A, Tulkens PM, Vlieghe E, Verbrugghe W, Jorens PG, Ieven M (2012) Continuous infusion of antibiotics in the critically ill: the new holy grail for beta-lactams and vancomycin? Ann Intensive Care 2:22
Roberts JA, Ulldemolins M, Roberts MS, McWhinney B, Ungerer J, Paterson DL, Lipman J (2010) Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents 36:332–339
Udy AA, Varghese JM, Altukroni M, Briscoe S, McWhinney BC, Ungerer JP, Lipman J, Roberts JA (2012) Subtherapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest 142:30–39
Craig WA (1998) Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26:1–10
Dahl M-L, Bertilsson L (1993) Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics 3:61–70
Jerling M, Lindström L, Bondesson U, Bertilsson L (1994) Fluvoxamine inhibition and carebamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 16:368–374
Bertilsson L, Carrillo JA, Dahl M-L, LLerena A, Alm C, Bondesson U, Lindström L, Rodriquez de la Rubia I, Ramos S, Benitez J (1994) Clozapine disposition covaries with the CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 38:471–473
Bengtsson F (2004) Therapeutic drug monitoring of psychotropic drugs, TDM “nouveau”. Ther Drug Monit 26:145–151
Brünen S, Vincent PD, Baumann P, Hiemke C, Havemann-Reinecke U (2011) Therapeutic drug monitoring for drugs used in the treatment fo substance-related disorders: Literature review using a therapeutic drug monitoring appropriateness rating scale. Ther Drug Monit 33:561–572
Carlquist JF, Anderson JL (2011) Using pharmacogenetics in real time to guide warfarin initiation: a clinician update. Circulation 124:2554–2559
Lindh JD, Holm L, Andersson ML, Rane A (2009) Influence of CYP2C9 genotype on warfarin dose requirements—a systematic review and meta-analysis. Eur J Clin Pharmacol 65:365–375
Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJ, Bumpstead S, Holm L, McGinnis R, Rane A, Deloukas P (2009) The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113:784–792
Lazo-Langner A, Kovacs MJ (2010) Predicting warfarin dose. Curr Opin Pulm Med 16:426–431
Malmström RE (2009) New anticoagulants: focus on currently approved oral factor Xa and factor IIa inhibitors. In: Antovic JP, Blombäck M (eds) Essential guide to blood coagulation. Wiley-Blackwell, Oxford, pp 91–102
Conolly SJ, for the RE-LY Steering Committee and Investigators et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151
Patel MR et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365(10):883–891
Granger CB et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365(11):981–992
Federal Drug Administration (2010) Questions dabigatran. Available at: www.fda.gov
European Medicines Agency (EMA). Summary of product characteristics. Pradaxa (dabigatran). Available at: www.ema.europa.eu
European Medicines Agency (EMA). Summary of product characteristics. Xarelto (rivaroxaban). Available at: www.ema.europa.eu
European Medicines Agency (EMA).Summary of product characteristics. Eliquis (apixaban). Available at: www.ema.europa.eu
Samama MM, Guinet C, Le Flem L, Ninin E, Debue JM (2013) Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study. J Thromb Thrombolysis 35:140–146
Antovic JP, Skeppholm M, Eintrei J, Eriksson-Boija E, Söderblom L, Rönquist Y, Pohanka A, Beck O, Norberg E-M, Hjemdahl P, Malmström RE (2013). How to monitor dabigatran when needed: comparison of coagulation laboratory methods and dabigatran concentrations in plasma. Abstract. 24th ISTH Congress and 59th Annual Scientific and Standardization Committee (SSC) Meeting, Amsterdam
Conflict of interests
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Eliasson, E., Lindh, J.D., Malmström, R.E. et al. Therapeutic drug monitoring for tomorrow. Eur J Clin Pharmacol 69 (Suppl 1), 25–32 (2013). https://doi.org/10.1007/s00228-013-1504-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-013-1504-x